CA3001321A1 - Methods of treating injuries or conditions related to cns edema - Google Patents
Methods of treating injuries or conditions related to cns edema Download PDFInfo
- Publication number
- CA3001321A1 CA3001321A1 CA3001321A CA3001321A CA3001321A1 CA 3001321 A1 CA3001321 A1 CA 3001321A1 CA 3001321 A CA3001321 A CA 3001321A CA 3001321 A CA3001321 A CA 3001321A CA 3001321 A1 CA3001321 A1 CA 3001321A1
- Authority
- CA
- Canada
- Prior art keywords
- subject
- administering
- sur1
- hours
- injury
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562238461P | 2015-10-07 | 2015-10-07 | |
| US62/238,461 | 2015-10-07 | ||
| PCT/US2016/055988 WO2017062765A1 (en) | 2015-10-07 | 2016-10-07 | Methods of treating injuries or conditions related to cns edema |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3001321A1 true CA3001321A1 (en) | 2017-04-13 |
Family
ID=58488580
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3001321A Pending CA3001321A1 (en) | 2015-10-07 | 2016-10-07 | Methods of treating injuries or conditions related to cns edema |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US20180280325A1 (https=) |
| EP (1) | EP3359162B1 (https=) |
| JP (4) | JP7349786B2 (https=) |
| KR (2) | KR102681027B1 (https=) |
| CN (2) | CN108348534A (https=) |
| AU (3) | AU2016335767B2 (https=) |
| BR (1) | BR112018006925A2 (https=) |
| CA (1) | CA3001321A1 (https=) |
| EA (1) | EA201890893A1 (https=) |
| ES (1) | ES2940669T3 (https=) |
| HK (1) | HK1257542A1 (https=) |
| IL (1) | IL258509B2 (https=) |
| MA (1) | MA45574A (https=) |
| MX (1) | MX392466B (https=) |
| WO (1) | WO2017062765A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6238969B2 (ja) | 2012-05-08 | 2017-11-29 | エアロミクス・インコーポレイテッドＡｅｒｏｍｉｃｓ，Ｉｎｃ． | 新規方法 |
| WO2015069956A2 (en) | 2013-11-06 | 2015-05-14 | Aeromics, Llc | Novel formulations |
| CA3001321A1 (en) * | 2015-10-07 | 2017-04-13 | Biogen Chesapeake Llc | Methods of treating injuries or conditions related to cns edema |
| WO2020041905A1 (en) * | 2018-08-31 | 2020-03-05 | The University Of British Columbia | Methods for identifying compounds suitable for treatment of central nervous system trauma and uses of those compounds |
| MA55813A (fr) * | 2019-05-02 | 2022-03-09 | Biogen Chesapeake Llc | Procédé de traitement de sujets souffrant de contusions du système nerveux central |
| CN120004770A (zh) * | 2020-07-17 | 2025-05-16 | 上海森辉医药有限公司 | 磺酰脲类衍生物及其医药用途 |
| US12251389B1 (en) * | 2024-04-22 | 2025-03-18 | Remedy Pharmaceuticals, Inc. | Methods of treating ischemic stroke at risk for cerebral or cerebellar edema |
| WO2025212155A1 (en) * | 2024-04-05 | 2025-10-09 | Remedy Pharmaceuticals, Inc. | Methods of treating ischemic stroke with large vessel occlusion using a sur1-trpm4 channel inhibitor |
| US12251388B1 (en) | 2024-05-09 | 2025-03-18 | Remedy Pharmaceuticals, Inc. | Methods of treating ischemic stroke at risk for cerebral or cerebellar edema |
| WO2025212189A1 (en) * | 2024-04-05 | 2025-10-09 | Remedy Pharmaceuticals, Inc. | Methods of treating ischemic stroke at risk for cerebral or cerebellar edema using a sur1-trpm4 channel inhibitor |
| WO2025212154A1 (en) * | 2024-04-05 | 2025-10-09 | Remedy Pharmaceuticals, Inc. | Methods of treating ischemic stroke at risk for cerebral or cerebellar edema |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5856360A (en) | 1996-05-03 | 1999-01-05 | Children's Hospital Medical Center | Pharmaceutical method for the treatment of severe blood loss and for the inhibition or treatment of hemorrhagic shock |
| US8980952B2 (en) * | 2002-03-20 | 2015-03-17 | University Of Maryland, Baltimore | Methods for treating brain swelling with a compound that blocks a non-selective cation channel |
| EP2438913B1 (en) | 2002-03-20 | 2020-05-06 | University of Maryland, Baltimore | A non-selective cation channel in neural cells and compounds that block the channel for use in treating brain swelling |
| US20050246000A1 (en) * | 2004-05-03 | 2005-11-03 | Seacoast Technologies, Inc. | Cooled craniectomy |
| WO2009002832A2 (en) | 2007-06-22 | 2008-12-31 | University Of Maryland, Baltimore | Inhibitors of ncca-atp channels for therapy |
| PT2868315T (pt) * | 2007-12-04 | 2017-09-04 | Remedy Pharmaceuticals Inc | Formulações melhoradas e métodos para liofilização e liofilizados assim produzidos |
| EP3339190A1 (en) * | 2010-07-19 | 2018-06-27 | Biogen Chesapeake LLC | Containers for glyburide solutions |
| CA3001321A1 (en) * | 2015-10-07 | 2017-04-13 | Biogen Chesapeake Llc | Methods of treating injuries or conditions related to cns edema |
-
2016
- 2016-10-07 CA CA3001321A patent/CA3001321A1/en active Pending
- 2016-10-07 MA MA045574A patent/MA45574A/fr unknown
- 2016-10-07 CN CN201680066630.6A patent/CN108348534A/zh active Pending
- 2016-10-07 KR KR1020187012950A patent/KR102681027B1/ko active Active
- 2016-10-07 EA EA201890893A patent/EA201890893A1/ru unknown
- 2016-10-07 HK HK18116503.6A patent/HK1257542A1/zh unknown
- 2016-10-07 KR KR1020247021781A patent/KR20240105519A/ko not_active Ceased
- 2016-10-07 US US15/763,932 patent/US20180280325A1/en not_active Abandoned
- 2016-10-07 ES ES16854422T patent/ES2940669T3/es active Active
- 2016-10-07 CN CN202211412393.8A patent/CN115737816A/zh active Pending
- 2016-10-07 AU AU2016335767A patent/AU2016335767B2/en active Active
- 2016-10-07 WO PCT/US2016/055988 patent/WO2017062765A1/en not_active Ceased
- 2016-10-07 EP EP16854422.9A patent/EP3359162B1/en active Active
- 2016-10-07 JP JP2018517841A patent/JP7349786B2/ja active Active
- 2016-10-07 BR BR112018006925A patent/BR112018006925A2/pt not_active Application Discontinuation
- 2016-10-07 MX MX2018004286A patent/MX392466B/es unknown
- 2016-10-07 IL IL258509A patent/IL258509B2/en unknown
-
2021
- 2021-02-16 JP JP2021022562A patent/JP2021073317A/ja not_active Withdrawn
- 2021-09-29 US US17/488,591 patent/US11951085B2/en active Active
-
2022
- 2022-11-28 AU AU2022279369A patent/AU2022279369B2/en active Active
-
2023
- 2023-02-13 JP JP2023020327A patent/JP7592768B2/ja active Active
-
2024
- 2024-03-04 US US18/595,205 patent/US20240216309A1/en active Pending
- 2024-08-23 JP JP2024142687A patent/JP7810762B2/ja active Active
- 2024-09-30 US US18/902,504 patent/US20250017880A1/en active Pending
-
2025
- 2025-04-14 AU AU2025202620A patent/AU2025202620A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11951085B2 (en) | Methods of treating injuries or conditions related to CNS edema | |
| Le et al. | Laser interstitial thermal therapy (LITT): seizure outcomes for refractory mesial temporal lobe epilepsy | |
| Liotta | Management of cerebral edema, brain compression, and intracranial pressure | |
| Nagy et al. | Contemporary radiosurgery of cerebral cavernous malformations: Part 2. Treatment outcome for hemispheric lesions | |
| EP3490545B1 (en) | Methods of medical treatment with sur1-trpm4 channel inhibitors | |
| Chatterjee et al. | Effectiveness of granisetron in prevention of hypotension following spinal anaesthesia in patients undergoing elective caesarean section | |
| Fogarty-Mack et al. | Superselective intraarterial papaverine administration: effect on regional cerebral blood flow in patients with arteriovenous malformations | |
| US20220226353A1 (en) | Method for treating subjects suffering from central nervous system contusions | |
| JP2026069546A (ja) | Ｃｎｓ浮腫に関連する損傷または状態を処置する方法 | |
| Ren et al. | Effect of methoxymine on prevention and treatment of myocardial injury and cardiac function in elderly patients with hypotension during intraspinal anesthesia. | |
| US20260115210A1 (en) | Method for treating subjects suffering from central nervous system contusions | |
| Khijmatgar et al. | Observational studies on the efficacy of carbamazepine and ascorbyl palmitate in managing trigeminal neuralgia | |
| WO2025193971A1 (en) | Methods of treating and reducing the likelihood of developing epilepsy | |
| Baig et al. | NFB-06. TREATMENT CHALLENGES IN PEDIATRIC GLIOBLASTOMA MULTIFORME WITH CONCURRENT SOMATIC AND GERMLINE NF1 MUTATIONS WITH GERMLINE MISMATCH REPAIR MUTATIONS: TWO UNIQUE CASES | |
| Chahal et al. | Effect of intravenous dexmedetomidine on sensory block duration in spinal anesthesia for lower limb surgery: a randomized controlled trial | |
| Hasanein et al. | Extending labor epidural analgesia using lidocaine plus either dexmedetomidine or epinephrine for emergency cesarean section | |
| Tempelhoff et al. | Avoiding Complications in Neuroanesthesia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20210907 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D11-D131 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION (RCE) RECEIVED Effective date: 20240910 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD Year of fee payment: 8 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240923 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240923 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240923 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20240923 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D174 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250828 Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D148 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION (NOA/CNOA) DETERMINED COMPLIANT Effective date: 20250828 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250828 |
|
| P12 | Request for amendment of application rejected |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P12-P147 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REJECTED AMENDMENT AFTER RCE - PREVIOUSLY ACCEPTED AMENDMENT AFTER ALLOWANCE REJECTED Effective date: 20250828 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250828 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250828 Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250828 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 9TH ANNIV.) - STANDARD Year of fee payment: 9 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250924 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250924 |